RaySearch Laboratories AB (0GRZ) AI Stock Analysis
Top Page
RaySearch Laboratories AB
(LSE:0GRZ)
No summary available
RaySearch Laboratories AB (0GRZ) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- SEK 602.69M
- Dividend Yield
- 1.56%
- Average Volume (3M)
- 21.50K
- Price to Earnings (P/E)
- 32.7
- Beta (1Y)
- 0.74
- Revenue Growth
- 1.42%
- EPS Growth
- 10.40%
- Country
- UK
- Employees
- 464
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Healthcare Information Services
RaySearch Laboratories AB Business Overview & Revenue Model
Company Description
RaySearch Laboratories AB (publ) is a global medical technology company dedicated to developing cutting-edge software solutions for cancer treatment. Its principal offering, RayStation, is a sophisticated treatment planning system that supports a vas...
RaySearch Laboratories AB Earnings Call Summary
The call reported a clearly disappointing Q2 with meaningful declines in license and hardware sales (license -18%, hardware -38%, net sales -11%) and a compressed EBIT margin (10%). However, several positive indicators offset the weakness: order intake grew 23%, backlog remains robust at SEK 1.691 billion (SEK 670 million expected to convert within 12 months), LTM organic growth was 9% with a 22% LTM EBIT margin, notable strategic wins (Dana-Farber and other U.S. orders recovered in early Q3), clinical milestones (online adaptive treatments on TrueBeam), product releases and strengthened proton expertise, improved cash flow (Q2 free cash flow SEK 50 million) and active share repurchases. Management believes a strong H2 can restore the year’s financial trajectory but execution risk remains. Overall, the positive backlog, early Q3 order recoveries and recurring revenue stability balance the quarter’s operational weaknesses and timing risks.
Q2-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management reiterated an unchanged operating margin target of at least 25% for 2026 and said it expects a strong H2 with recovery of orders slipped from Q2 (management said the Q2 slips should be recovered in Q3 and noted 9 RayStation orders in July worth ~USD 5m). Key numbers referenced alongside that guidance: Q2 net sales SEK 272m (down 11%, organic -8%), Q2 EBIT SEK 28m (10% margin) and recurring support revenue SEK 133m (49% of Q2 revenue); last 12 months net sales SEK 1.27bn (organic growth 9%) with EBIT SEK 277m (22% margin) and recurring support 41% of revenue. Order intake was up 23%, book-to-bill 1.1, order backlog SEK 1.691bn (SEK 670m expected to convert to sales in the next 12 months), free cash flow in Q2 SEK 50m, cash SEK 213m, advances from customers SEK 390m, share repurchases SEK 200m (995,558 shares, 2.9% of registered shares), and a new rolling credit facility of SEK 225m; management said achieving the margin target will require significant sales growth (aiming for double‑digit growth).
RaySearch Laboratories AB Peers Comparison
Overall Rating
SE:SECT.B79Outperform
SE:SUS68Neutral
SE:PAX60Neutral
SE:CRAD.B58Neutral
SE:MNTC58Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| SE:SECT.B | 79Outperform | SEK 67.51B | 105.81 | 30.26% | 0.38% | 13.94% | 5.70% |
| SE:SUS | 68Neutral | SEK 3.00B | 32.16 | ― | ― | 8.40% | 0.74% |
| SE:PAX | 60Neutral | SEK 1.54B | -303.85 | -1.22% | ― | 34.05% | -144.96% |
| SE:CRAD.B | 58Neutral | SEK 783.39M | 16.48 | 13.23% | 0.43% | -8.76% | 103.87% |
| SE:MNTC | 58Neutral | SEK 435.95M | -90.48 | -3.61% | ― | 15.87% | 92.43% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0GRZ | RaySearch Laboratories AB Class B | 202.20 | -17.21 | -7.84% | |
| SE:PAX | Paxman AB | 66.30 | -1.10 | -1.63% | |
| SE:CRAD.B | C-Rad AB Class B | 23.20 | -9.80 | -29.69% | |
| SE:SECT.B | Sectra AB Class B | 346.00 | 49.17 | 16.56% | |
| SE:MNTC | Mentice AB | 15.50 | 6.02 | 63.50% | |
| SE:SUS | Surgical Science Sweden AB | 58.85 | -23.65 | -28.67% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.